A 70,000 square-foot facility in the heart of the Kendall Square, Cambridge, biotech innovation hub, LabCentral is a first-of-its-kind shared laboratory space designed as a launchpad for high-potential life-sciences and biotech startups. It offers fully permitted laboratory and office space for as many as 60 startups comprising approximately 200 scientists and entrepreneurs. LabCentral provides first-class facility and administrative support, skilled laboratory personnel, a domain-relevant expert speaker series ‒ as well as the other critical services and support that early-stage companies need to begin laboratory operations on day one. A private, nonprofit institution, LabCentral was funded in part by two $5 million grants from the Massachusetts Life Sciences Center, with support from its real-estate partner, MIT. Founding sponsors include Triumvirate Environmental and Johnson & Johnson Innovation. The first startups joined us in early November, with lab operations launching officially November 15, 2013.
To accommodate demand for its growing startups, LabCentral, with support from Pfizer, Inc., opened LabCentral 610 in December 2017. With the addition of this 33,000 square-foot facility, capable of supporting up to six early- to mid-stage companies, by 2018, LabCentral will have capacity to serve a total of ~450 scientists and entrepreneurs in about 70 companies across its two-building campus.
Our mission is to help create the next generation of powerhouse biotech companies by providing entrepreneurs and innovative life-sciences startups with the space and resources they need to test out, challenge, and nurture early ideas.
To accommodate demand for its growing startups, LabCentral, with support from Pfizer, Inc., opened LabCentral 610 in December 2017. With the addition of this 33,000 square-foot facility, capable of supporting up to six early- to mid-stage companies, by 2018, LabCentral will have capacity to serve a total of ~450 scientists and entrepreneurs in about 70 companies across its two-building campus.
Our mission is to help create the next generation of powerhouse biotech companies by providing entrepreneurs and innovative life-sciences startups with the space and resources they need to test out, challenge, and nurture early ideas.
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Total raised: $22.4M
Founded date: 2012
Founders name: Timothy Rowe
Founders Related Locations: United States, Massachusetts, Boston; United States, Massachusetts, Cambridge
Investors 2
| Date | Name | Website |
| 06.07.2021 | New Enterp... | nea.com |
| - | MRL Ventur... | mrlv.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 18.02.2021 | - | $22.4M | - |
Persons 2
| Date | First Name | Last Name | Title | Location | |||
| - | Timothy | Rowe | Co-Founder... | linkedin.c... | - | - | - |
| - | Jo | Viney | Board of D... | linkedin.c... | - | - | United Sta... |
Mentions in press and media 31
| Date | Title | Description |
| 14.10.2025 | Jeio Tech Partners with LabCentral to Empower Early-Stage Biotech Startups | Jeio Tech Partners with LabCentral Jeio Tech Equipment in LabCentral Jeio Tech's Global Branch and Partners in over 80 Countries LabCentral Sponsor Wall Jeio Tech joins LabCentral to provide advanced lab equipment, supporting biotech startu... |
| 27.04.2025 | ONO PHARMA USA Announces 2025 Golden Ticket CompetitionNow Accepting Applications from Innovative Startups | Ono Partnering with LabCentral and MBC BioLabs for Fifth Consecutive Year CAMBRIDGE, Mass., April 27, 2025 /PRNewswire/ -- ONO PHARMA USA today announced partnerships with LabCentral in Cambridge, Mass., and MBC BioLabs in San Francisco and... |
| 10.07.2024 | BOLDEN THERAPEUTICS TO PRESENT AT THE 4TH ANNUAL OLIGONUCLEOTIDES FOR CNS SUMMIT | PROVIDENCE, R.I., July 10, 2024 /PRNewswire/ -- Bolden Therapeutics, Inc., a biotechnology company developing first-in-class therapeutics to promote neurogenesis for the potential treatment of CNS illnesses, today announced their invitation... |
| 26.08.2021 | LabCentral Launches Inaugural LabCentral Ignite Golden Ticket Program | |
| 08.04.2021 | LabCentral Releases 2020 Impact Report: Companies Raised $3.7 Billion in Funding and 33% of 2020 Massachusetts Bio-Pharma IPOs Started in the LabCentral Network | |
| 18.02.2021 | LabCentral Announces $22.4 Million in Committed Funding for LabCentral 238 including New Sponsors Thermo Fisher Scientific and Waters Corporation | |
| 29.10.2020 | LabCentral Launches COVID-19 Rapid Testing Consortium in Partnership with BioLabs and E25Bio | |
| 08.10.2020 | Astellas and LabCentral Announce Golden Ticket Winners - Helping Emerging Biotechs Accelerate Growth of Innovative Science | |
| 01.10.2019 | LabCentral Gets $13 Million Cash Infusion, Set to Open New Incubator | LabCentral, the Cambridge-based research laboratory, is set to open a new incubator focused on "scale-up biomanufacturing" in 2021. The initiative is fueled by investment from Astellas Pharma, a 14-year-old pharmaceutical company ... |
| 15.08.2019 | The Creation Of Biotech Startups: Evolution Not Revolution | The startup paradigm for the creation and funding of new biotech companies has evolved enormously over the past two decades. Recently there’s been a pair of articles from Tech VCs about applying alternative models of company creation (here,... |
Show more